Latest News in the pharma Industry

Policy & Regulation

Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases

Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases

14 Jul 2016

Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product.

Read more 
Pfizer receives FDA approval for Prevnar 13 in adults age 18 through 49

Pfizer receives FDA approval for Prevnar 13 in adults age 18 through 49

13 Jul 2016

Prevnar 13 is the only pneumococcal vaccine approved in the US for patients 6 weeks through adulthood.

Read more 
FDA Approves Shire’s Xiidra

FDA Approves Shire’s Xiidra

12 Jul 2016

Xiidra is the only treatment Indicated for the signs and symptoms of dry eye disease.

Read more 
Scots first to receive breakthrough immunotherapy for lung cancer

Scots first to receive breakthrough immunotherapy for lung cancer

11 Jul 2016

Eligible patients in Scotland will be the first in the UK to access this life-extending treatment and will be ahead of those patients in England and Wales.

Read more 
FDA approves first and only single monthly injection for a PCSK9 inhibitor

FDA approves first and only single monthly injection for a PCSK9 inhibitor

11 Jul 2016

Amgen's Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge) provides a new, monthly single-dose administration option.

Read more 
EC grants marketing authorization for Gilead’s Epclusa for the treatment of all genotypes of chronic hepatitis C

EC grants marketing authorization for Gilead’s Epclusa for the treatment of all genotypes of chronic hepatitis C

10 Jul 2016

Epclusa is the first and only all-oral, single tablet regimen for all genotypes (1-6) of chronic hepatitis C virus infection and is Gilead’s third Sofosbuvir-based treatment.

Read more 
FDA approves Genentech’s Xolair for allergic asthma in children

FDA approves Genentech’s Xolair for allergic asthma in children

8 Jul 2016

Approval makes Xolair the only biologic for children ages six and up with uncontrolled allergic asthma.

Read more 
Shire receives extension of Market Authorization in Europe for Revestive

Shire receives extension of Market Authorization in Europe for Revestive

7 Jul 2016

First therapy indicated in the EU for use in patients aged one year and above with Short Bowel Syndrome, a rare gastrointestinal condition.

Read more 
EC approves extended indication for Amgen's Kyprolis

EC approves extended indication for Amgen's Kyprolis

4 Jul 2016

Head-to-head Phase III trial demonstrated superiority of Kyprolis and dexamethasone over Velcade and dexamethasone in patients with relapsed multiple myeloma.

Read more 
Chinese authorities issue operating approval to Siegfried Nantong

Chinese authorities issue operating approval to Siegfried Nantong

30 Jun 2016

This significant site addition to Siegfried’s production network strengthens the company’s long-term competitiveness.

Read more 
FDA Advisory Committee recommends approval of Jardiance for cardiovascular indication

FDA Advisory Committee recommends approval of Jardiance for cardiovascular indication

29 Jun 2016

Endocrinologic and Metabolic Drugs Advisory Committee votes in favour of cardiovascular mortality benefit for JARDIANCE for adults with type 2 diabetes.

Read more 
BMS Opdivo receives Breakthrough Therapy Designation from FDA for advanced form of bladder cancer

BMS Opdivo receives Breakthrough Therapy Designation from FDA for advanced form of bladder cancer

27 Jun 2016

This milestone marks the sixth Breakthrough Therapy Designation for Opdivo.

Read more